Lemaitre Vascular Inc. (LMAT)
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre (LMAT) Upgraded to Buy: Here's Why
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.48 per share a year ago.
LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, LeMaitre Vascular, Inc. (LMAT) could be a good stock pick from a technical perspective. LMAT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
LeMaitre Vascular: The Compounder Keeps Compounding
LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft's international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program.
LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript
3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre Vascular (LMAT) Q3 Earnings Surpass Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.49 per share a year ago.
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
